3 ANNEX III Requirements concerning the formulation of antigens of the foot and mouth disease virus into vaccines and the labelling of the ready-to-use vaccine as referred to in Article 5, Regulation (EU) 2022/140

In forcesince 16 Nov 2021
1.

The formulation of the antigen(s) into vaccines shall be performed as follows:

(a)

as regards those for immediate supply: the contracted manufacturer shall formulate, bottle and label a minimum of 300000 doses and a maximum of 2000000 doses of finished vaccine (Al(OH)3/Saponin and/or DOE) per formulation site during the period of 6 working days following the date of notice of the request for delivery by the Commission; or

(b)

as regards those for urgent but not immediate supply: the contracted manufacturer shall formulate, bottle and label a minimum of 300000 doses up to a maximum of 2000000 doses of finished vaccine (Al(OH)3/Saponin and/or DOE) per formulation site during a period of between 7 to 15 working days following the date of notice of the request for delivery by the Commission.

2.

The biggest requisition may be up to 5 million doses of each of the 4 different antigens from the stock of antigens in the Union antigen, vaccine and diagnostic reagent banks formulated into 5 million doses of a tetravalent vaccine.

3.

The minimum potency of vaccines formulated from the stocks of antigens in the Union antigen, vaccine and diagnostic reagent banks shall be at least 6 PD50.

4.

The bottling, labelling and distribution of the vaccine shall be carried out taking into account the specific needs of the area where vaccination is to be carried out.

5.

The labelling of the ready-to-use vaccine shall be in accordance with the marketing authorisation for Al(OH)3/Saponin and/or DOE vaccine adjuvants adapted in accordance with the contract referred to in Article 3(1) or 4(1) of Delegated Regulation (EU) 2022/139.

6.

The boxes containing the vaccines shall have the following label in A4 format: